HUP0303927A2 - Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre - Google Patents
Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésreInfo
- Publication number
- HUP0303927A2 HUP0303927A2 HU0303927A HUP0303927A HUP0303927A2 HU P0303927 A2 HUP0303927 A2 HU P0303927A2 HU 0303927 A HU0303927 A HU 0303927A HU P0303927 A HUP0303927 A HU P0303927A HU P0303927 A2 HUP0303927 A2 HU P0303927A2
- Authority
- HU
- Hungary
- Prior art keywords
- tnf
- agents
- angiogenic agents
- alpha
- combination therapy
- Prior art date
Links
- 239000004037 angiogenesis inhibitor Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 101150106931 IFNG gene Proteins 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940044627 gamma-interferon Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011294 monotherapeutic Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
találmány tárgya daganatok és áttéteik elleni kombinációs kezelés,melynek során a következőket adják be: anti-angiogén ágenseket és a-tumor nekrózis faktort (TNF-a), adott esetben más citotoxikus ágenssel- például gamma-interferonnal (IFNg) - vagy kemoterápiás ágenssel -például EGFR-ellenes antitestekkel - társítva. Az eljárás valamint afenti ágenseket tartalmazó gyógyászati készítmények szinergista módonerősíthetik az egyes terápiás ágensek tumorsejt-proliferációt gátlóhatását, ami hatékonyabb kezelést eredményezhet, mint az egyeskomponensek monoterápiás alkalmazása. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01109981 | 2001-04-24 | ||
PCT/EP2002/004298 WO2002085405A2 (en) | 2001-04-24 | 2002-04-18 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a) |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0303927A2 true HUP0303927A2 (hu) | 2004-03-01 |
HUP0303927A3 HUP0303927A3 (en) | 2006-03-28 |
Family
ID=8177227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303927A HUP0303927A3 (en) | 2001-04-24 | 2002-04-18 | Combination therapy using anti-angiogenic agents and tnf-alpha |
Country Status (20)
Country | Link |
---|---|
US (3) | US20040136949A1 (hu) |
EP (2) | EP2292251A1 (hu) |
JP (2) | JP4660067B2 (hu) |
KR (1) | KR100861466B1 (hu) |
CN (1) | CN1247258C (hu) |
AT (1) | ATE510557T1 (hu) |
AU (1) | AU2002316855B2 (hu) |
BR (1) | BR0209114A (hu) |
CA (1) | CA2444821C (hu) |
CZ (1) | CZ20033119A3 (hu) |
DK (1) | DK1381384T3 (hu) |
ES (1) | ES2366775T3 (hu) |
HU (1) | HUP0303927A3 (hu) |
MX (1) | MXPA03009683A (hu) |
PL (1) | PL363311A1 (hu) |
PT (1) | PT1381384E (hu) |
RU (1) | RU2316337C2 (hu) |
SK (1) | SK14272003A3 (hu) |
WO (1) | WO2002085405A2 (hu) |
ZA (1) | ZA200309060B (hu) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2316337C2 (ru) * | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
CA2541709C (en) | 2003-11-13 | 2013-06-04 | California Pacific Medical Center | Anti-pecam therapy for metastasis suppression |
MXPA06010667A (es) * | 2004-03-19 | 2007-07-04 | Penn State Res Found | Metodos combinatorios y composiciones para el tratamiento de melanoma. |
CN101102791B (zh) * | 2004-11-18 | 2011-12-14 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
JP2008525424A (ja) | 2004-12-23 | 2008-07-17 | モルメド エスピーエー | 複合生成物 |
WO2006074370A2 (en) * | 2005-01-07 | 2006-07-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Agonists and antagonists of tnfrii/cd120b for treatment of immune-related diseases |
US20110165150A1 (en) * | 2006-01-18 | 2011-07-07 | Merck Patent Gmbh | Isolated organ perfusion combination therapy of cancer |
PL2101805T3 (pl) * | 2007-01-18 | 2013-04-30 | Merck Patent Gmbh | Ligandy integryn do stosowania w leczeniu nowotworów |
WO2008103301A2 (en) * | 2007-02-16 | 2008-08-28 | President And Fellows Of Harvard College | Treatment of the eye using macrophages and/or agents able to affect blood vessel morphology |
BRPI0909180A2 (pt) | 2008-03-13 | 2016-08-09 | Biotest Ag | composição farmacêutica, e, método de tratamento de uma doença autoimune |
ES2610327T3 (es) | 2008-03-13 | 2017-04-27 | Biotest Ag | Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias |
US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
PT2288367E (pt) * | 2008-05-16 | 2016-02-09 | Corthera Inc | Relaxina h2 para utilização no tratamento da dilatação cervical prematura |
FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
MX2011003335A (es) * | 2008-09-29 | 2011-04-27 | Biotest Ag | Composicion para tratar enfermedad. |
MX2011004252A (es) * | 2008-10-23 | 2012-01-27 | Steba Biotech N V | Peptidomiméticos que contienen arginina-glicina-ácido aspártato y usos de los mismos. |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
DK2524693T3 (da) | 2010-01-14 | 2014-08-25 | Sanwa Kagaku Kenkyusho Co | Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet |
WO2011103583A2 (en) * | 2010-02-22 | 2011-08-25 | University Of Chicago | Methods and compositions related to anti-angiogenic peptides |
US20130323167A1 (en) * | 2010-10-21 | 2013-12-05 | The Johns Hopkins University | Detecting and treating solid tumors through selective disruption of tumor vasculature |
JPWO2012105610A1 (ja) | 2011-02-02 | 2014-07-03 | 株式会社三和化学研究所 | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
RU2530592C2 (ru) * | 2012-07-20 | 2014-10-10 | Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) | Способ подавления роста опухолей |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
CN112569358B (zh) * | 2019-09-30 | 2022-06-28 | 上海生物制品研究所有限责任公司 | 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4503035B1 (en) | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
WO1992010209A1 (en) | 1990-12-04 | 1992-06-25 | The Wistar Institute Of Anatomy And Biology | Bifunctional antibodies and method of preparing same |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
SK281142B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
CA2143263C (en) * | 1994-03-02 | 2002-01-08 | Kerry John Hartauer | Orally administrable raloxifene formulations |
US5656655A (en) | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5741796A (en) | 1994-05-27 | 1998-04-21 | Merck & Co., Inc. | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption |
JPH10504807A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
JPH10504808A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
US6008214A (en) | 1994-08-22 | 1999-12-28 | Smithkline Beecham Corporation | Bicyclic compounds |
DK0719859T3 (da) | 1994-12-20 | 2003-10-20 | Merck Patent Gmbh | Anti-alfa V-integrin monoklonalt antistof |
WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
SI0910563T1 (en) | 1995-06-29 | 2003-10-31 | Smithkline Beecham Corporation | Integrin receptor antagonists |
DE19534177A1 (de) * | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
CN1202932A (zh) | 1995-10-23 | 1998-12-23 | 儿童医学中心公司 | 治疗用抗血管生成的组合物和方法 |
TR199801254T2 (xx) | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r� antagonistleri. |
CA2241724A1 (en) | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
CZ203698A3 (cs) | 1995-12-29 | 1999-05-12 | Smithkline Beecham Corporation | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití |
SK282894B6 (sk) | 1996-03-20 | 2003-01-09 | Hoechst Marion Roussel | Tricyklické zlúčeniny, spôsob ich prípravy a medziprodukty tohto spôsobu, ich použitie ako liečiv a farmaceutické zmesi, ktoré ich obsahujú |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
AU720758B2 (en) | 1996-04-10 | 2000-06-08 | Merck & Co., Inc. | Alphavbeta3 antagonists |
AU2438297A (en) | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
JP2002515036A (ja) | 1996-05-31 | 2002-05-21 | ザ スクリップス リサーチ インスティテュート | α▲下V▼β▲下5▼媒介血管形成の抑制に有用な方法および組成物 |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
EP0934305A4 (en) | 1996-08-29 | 2001-04-11 | Merck & Co Inc | INTEGRINE ANTAGONISTS |
EP0946180A4 (en) | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | METHODS FOR STIMULATING BONE FORMATION |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
AU717283B2 (en) | 1996-10-30 | 2000-03-23 | Merck & Co., Inc. | Integrin antagonists |
EP0946165B1 (en) | 1996-10-30 | 2003-04-09 | Merck & Co., Inc. | Integrin antagonists |
CA2272090A1 (en) | 1996-12-09 | 1998-06-18 | Matthew J. Fisher | Integrin antagonists |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
AU729869B2 (en) | 1997-01-17 | 2001-02-15 | Merck & Co., Inc. | Integrin antagonists |
US6590079B2 (en) * | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
AU6954398A (en) * | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
WO1999005107A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
EP1007051A4 (en) | 1997-08-04 | 2001-08-29 | Smithkline Beecham Corp | INTEGRIN RECEPTOR ANTAGONISTS |
JP2001514253A (ja) | 1997-09-04 | 2001-09-11 | スミスクライン・ビーチャム・コーポレイション | インテグリンレセプターアンタゴニスト |
PE122699A1 (es) | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
IL135188A0 (en) | 1997-09-24 | 2001-05-20 | Smithkline Beecham Corp | Vitronectin receptor antagonist |
TR200000792T2 (tr) | 1997-09-24 | 2000-09-21 | Smithkline Beecham Corporation | Vitronektin reseptör antagonistleri. |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
ATE299023T1 (de) | 1997-12-17 | 2005-07-15 | Merck & Co Inc | Integrinrezeptor antagonisten |
TR200001752T2 (tr) | 1997-12-17 | 2000-12-21 | Merck & Co., Inc. | Entegrin reseptör antagonistleri |
AU736026B2 (en) | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
HUP0100397A3 (en) | 1997-12-17 | 2002-10-28 | Merck & Co Inc | Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation |
CN1168741C (zh) | 1998-01-23 | 2004-09-29 | 默克专利股份有限公司 | 抗αv整联蛋白单克隆抗体及其在抑制αvβ6整联蛋白与纤连蛋白附着中的应用 |
AU747784B2 (en) | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
US6235877B1 (en) * | 1999-08-04 | 2001-05-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
WO2000038730A2 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
DE60035779T2 (de) | 1999-06-02 | 2008-04-30 | Merck & Co., Inc. | Alpha v integrin-rezeptor antagonisten |
US6627196B1 (en) * | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
RU2316337C2 (ru) * | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
-
2002
- 2002-04-18 RU RU2003132431/15A patent/RU2316337C2/ru not_active IP Right Cessation
- 2002-04-18 US US10/475,713 patent/US20040136949A1/en not_active Abandoned
- 2002-04-18 DK DK02745238.2T patent/DK1381384T3/da active
- 2002-04-18 BR BR0209114-3A patent/BR0209114A/pt not_active IP Right Cessation
- 2002-04-18 PL PL02363311A patent/PL363311A1/xx not_active Application Discontinuation
- 2002-04-18 AT AT02745238T patent/ATE510557T1/de active
- 2002-04-18 EP EP10010393A patent/EP2292251A1/en not_active Withdrawn
- 2002-04-18 CA CA2444821A patent/CA2444821C/en not_active Expired - Fee Related
- 2002-04-18 SK SK1427-2003A patent/SK14272003A3/sk not_active Application Discontinuation
- 2002-04-18 EP EP02745238A patent/EP1381384B1/en not_active Expired - Lifetime
- 2002-04-18 KR KR1020037013956A patent/KR100861466B1/ko not_active IP Right Cessation
- 2002-04-18 MX MXPA03009683A patent/MXPA03009683A/es active IP Right Grant
- 2002-04-18 WO PCT/EP2002/004298 patent/WO2002085405A2/en active Application Filing
- 2002-04-18 PT PT02745238T patent/PT1381384E/pt unknown
- 2002-04-18 JP JP2002582978A patent/JP4660067B2/ja not_active Expired - Fee Related
- 2002-04-18 AU AU2002316855A patent/AU2002316855B2/en not_active Ceased
- 2002-04-18 HU HU0303927A patent/HUP0303927A3/hu unknown
- 2002-04-18 CZ CZ20033119A patent/CZ20033119A3/cs unknown
- 2002-04-18 ES ES02745238T patent/ES2366775T3/es not_active Expired - Lifetime
- 2002-04-18 CN CNB02808876XA patent/CN1247258C/zh not_active Expired - Fee Related
-
2003
- 2003-11-20 ZA ZA200309060A patent/ZA200309060B/en unknown
-
2007
- 2007-09-04 US US11/849,685 patent/US20090035270A1/en not_active Abandoned
-
2009
- 2009-08-04 JP JP2009181445A patent/JP5178663B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-21 US US13/052,496 patent/US20110177027A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040136949A1 (en) | 2004-07-15 |
CN1247258C (zh) | 2006-03-29 |
KR20040030595A (ko) | 2004-04-09 |
WO2002085405A2 (en) | 2002-10-31 |
EP1381384A2 (en) | 2004-01-21 |
DK1381384T3 (da) | 2011-07-25 |
PT1381384E (pt) | 2011-09-01 |
KR100861466B1 (ko) | 2008-10-02 |
CN1505527A (zh) | 2004-06-16 |
CA2444821A1 (en) | 2002-10-31 |
AU2002316855B2 (en) | 2008-03-13 |
SK14272003A3 (sk) | 2004-04-06 |
BR0209114A (pt) | 2004-07-13 |
JP2004529149A (ja) | 2004-09-24 |
ZA200309060B (en) | 2005-02-21 |
HUP0303927A3 (en) | 2006-03-28 |
US20090035270A1 (en) | 2009-02-05 |
JP5178663B2 (ja) | 2013-04-10 |
JP2009256373A (ja) | 2009-11-05 |
MXPA03009683A (es) | 2004-02-12 |
CZ20033119A3 (cs) | 2005-01-12 |
EP1381384B1 (en) | 2011-05-25 |
EP2292251A1 (en) | 2011-03-09 |
US20110177027A1 (en) | 2011-07-21 |
ES2366775T3 (es) | 2011-10-25 |
WO2002085405A3 (en) | 2003-10-02 |
CA2444821C (en) | 2012-07-10 |
PL363311A1 (en) | 2004-11-15 |
RU2003132431A (ru) | 2005-04-10 |
JP4660067B2 (ja) | 2011-03-30 |
RU2316337C2 (ru) | 2008-02-10 |
ATE510557T1 (de) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303927A2 (hu) | Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre | |
HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
ATE307608T1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
WO2003094836A3 (en) | Methods and products for enhancing immune responses using imidazoquinoline compounds | |
MXPA05006670A (es) | Administracion de capsaicinoides. | |
DE60321929D1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
DK1173178T3 (da) | Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion | |
HUP0102489A2 (hu) | Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben | |
UA81628C2 (uk) | Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
WO2022012635A9 (zh) | 一种药物组合物及其用途 | |
DE60124387D1 (de) | Synergistische kombination zur behandlung von kolorektalkarzinom | |
MX2022007516A (es) | Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. | |
MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
HUP0401634A2 (hu) | LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására | |
MX2023006294A (es) | Proteinas de union a il-7 y su uso en tratamientos medicos. | |
EA200801670A1 (ru) | Комбинированная противораковая терапия с перфузией изолированного органа | |
Garufi et al. | Irinotecan and chronomodulated infusion of 5‐fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: A Phase I study | |
MXPA04009012A (es) | Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. | |
Vigani et al. | Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity | |
Patel-Yadav et al. | Acupuncture-like transcutaneous nerve stimulation therapy success after 5 years post-radiation-induced xerostomia: a case report | |
MXPA04009396A (es) | Combinacion que comprende un inhibidor cdk y doxorubicina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |